Heidelberg ImmunoTherapeutics GmbH is a clinical stage biopharmaceutical company focusing on the clinical development of innovative antibody-based immunotherapeutic for the treatment of viral diseases and cancer.

The company was founded as spin-off from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital in 2016. Our goal is to advance novel immunotherapeutic from preclinical research towards early phase I and II clinical trials. The company’s lead product, HDIT101, is designed to treat herpes simplex virus infections, which affect millions of people. An initial human study demonstrating the pharmacokinetics, safety and tolerability has been completed. Two phase II studies are currently ongoing in patients with recurrent HSV-2 positive genital herpes and in patients with orolabial HSV-1 infections.